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topical pharmaceutical excipients such as propylene glycol and glycerol, was withheld for the evaluation
of its health risk after dermal exposure.
An ex-vivo in-vitro permeation study using human skin in a Franz Diffusion Cell set-up and GC as
quantiﬁcation methodology showed a signiﬁcant skin penetration with an overall Kp value of 1.82 103
cm/h. Using these data, limit speciﬁcations after application of a dermal pharmaceutical product were
estimated. Based on the TTC approach of Cramer class I substances, i.e. 1800 mg/(day∙person), the
toxicity-qualiﬁed speciﬁcation limits of acetol in topical excipients were calculated to be 90 mg/mL and
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J. Boonen et al.304It is concluded that setting speciﬁcation limits for impurities within a quality-by-design approach requires
a case-by-case evaluation as demonstrated here with acetol.
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Drug products (DPs) contain active pharmaceutical ingredients
(APIs) or drug substances (DSs) and excipients. These excipients
or auxiliary substances, deﬁned as “any constituent of a medicinal
product that is not an active substance” [1] are intended to
guarantee the required physical, microbiological, chemical and
biopharmaceutical properties of the formulation. Contrary to APIs,
excipients fundamentally are pharmacologically inert. Neverthe-
less, they actually are important actors in the ﬁnal product. They
can exert not only pharmaceutical functions, but also toxicological
effects or might interact with active substances and hence modify
the biofunctionality [2]. However, the legal quality framework for
excipients is currently not so well developed as it is for APIs. Only
in recent ICH Q8/Q9 and the EC directive 2011/62/EU, excipients
are mentioned in a rather general and vague way. Next to the
“generic” impurities like residual solvents, heavy metals or
mycotoxins [3], more structurally related impurities can also be
present in excipients, for which no speciﬁc detailed regulatory
guidance is present [4]. Nevertheless, as the quality of excipients
cannot only signiﬁcantly inﬂuence the DP quality, but is also more
difﬁcult to control, it is expected that excipient quality will be
further developed in the years to come. Moreover, most often no
quality distinction towards impurities is made between the
intended routes of administration. It seems justiﬁed that higher
levels of impurities might be acceptable in certain cases such as
topical application. As part of the quality risk assessment during
product development, justiﬁcation for these impurity levels should
be made on a case-by-case basis. In this study, we will focus on
the risk of related impurities present in topical excipients. More-
over, acetol, a selected possible impurity in frequently used topical
excipients i.e. propylene glycol and glycerol, will be evaluated for
its toxicity risk after dermal application.2. Materials and methods
2.1. Impurities in topical excipients
To map the impurities present in topically applied excipients, a
database of excipients used in dermal drugs was created. Applying
the Handbook of Pharmaceutical excipients (4th edition) [5], an
exhaustive list of pharmaceutical excipients (n¼250) was obtained
(see Table A.1). To perform a complete search of dermal drugs,
the THERIAQUEs database (http://www.theriaque.org) was used
(June 2009). This database contains ofﬁcial regulatory and
validated bibliographical information about all drugs available in
France, considered as a representative country in Europe. The
“multi-choice search function”, allowing selection of drugs on
multiple criteria such as the name of the medicine or compounds
(active substance or excipient) and administration route, was used.
Administration way “cutaneous” OR “topical” OR “transdermal”
was selected as search criterion. After elimination of products with
identical composition but different packaging sizes, a total of 708
dermal drugs (NDD,total) was obtained. For each of the 250 excipients inthe pharmaceutical excipient database, the absolute number of dermal
drugs wherein they occur (NDD/excip), was tabulated (Table 1).
Excipients not present in the dermal drugs (n¼133) were excluded.
Hence, 117 excipients used in preparations for cutaneous applications
(dermal drugs) were retained for further analysis. From the absolute
number of dermal drugs in the 117 dermally used excipients, it was
calculated that in total 2499 excipients are used in the 708 dermal drugs
Nexcip;total ¼∑n ¼ 117i ¼ 1 NDD=excip. Hence, the relative frequency of occur
rence of one excipient in the total number of excipients used in dermal
drugs can be calculated as follows (Table 1):
Relative frequencyexcipð%Þ ¼ 100ðNDD=excip=Nexcip;totalÞ ð1Þ
The excipients were then ranked according to their relative
frequencyexcip (from high to low) and subsequently, the cumulative
frequencyexcip (%) was calculated. For the excipients covering
80% of the total use in dermal drugs, a literature-based impurity
database was created. The European Pharmacopoeia (Ph. Eur.) 7th
edition (2011), United States Pharmacopeia (USP) 32nd edition
(2010) and International Pharmacopoeia (Ph. Int.) 4th edition
(2011) as well as the search engines Web of Science, PubMed and
Google (Books) were consulted (dd. October 2011). The name of
the excipient and ‘impuritn’ were used with the Boolean operation
“AND”. Moreover, other possible impurities were searched for via
the published industrial synthesis routes of the excipients. Finally,
the in-silico toxicity of all found “related” impurities was
examined using Derek Nexus 2.0 (Lhasa Limited) software.2.2. Chemicals and reagents
Acetol, glycerol (ρ¼1.261 g/mL) and absolute ethanol (EtOH)
were supplied by Sigma Aldrich (Bornem, Belgium). N-butanol
and sodium sulfate (Na2SO4) were purchased from Merck
(Darmstadt, Germany). Ultrapure water (H2O) was produced by
an Arium 611 puriﬁcation system (Sartorius, Göttingen, Ger-
many), resulting in ultrapure water of 18.2 MΩ cm quality.
Acetone was obtained from Fisher Scientiﬁc (Leicestershire,
UK). Ethanol denatured with up to 5% ether was bought from
Chem Lab (Zedelgem, Belgium). 0.01 M phosphate buffered
saline (PBS) was purchased from Sigma (St. Louis, MO, USA).
Analytical grade propylene glycol (ρ¼1.036 g/mL) was supplied
by Riedel-de Haën (Seelze, Germany).2.3. Analytical methodology for acetol
2.3.1. Sample preparation
Aqueous receptor ﬂuid samples were generated during the FDC
experiment. To 200 mL aqueous samples, 100 mL acetone was
added. About 80 mg of anhydrous Na2SO4 was added to capture
the water. After vortexing and centrifugation, the supernatant was
collected. This water-removal procedure was repeated two more
times on the obtained supernatant.
Table 1 Frequency of topical excipients in dermal drugs.
# Excipient NDD/excip Relative frequencyexcip (%)
1 Water 438 17.53
2 Propylene glycol 191 7.64
3 Parafﬁn (¼hard wax) 165 6.60
4 Ethanol (¼alcohol) 146 5.84
5 Polyethylene glycol (¼macrogol) 140 5.60
6 Petrolatum (¼parafﬁn, yellow soft) 113 4.52
7 Carbomer (¼acrylic acid polymer) 91 3.72
8 Glycerol 90 3.60
9 Sodium hydroxide 68 2.72
10 Triethanolamine (¼ trolamine) 63 2.52
11 Cetyl alcohol 62 2.48
12 Isopropyl alcohol (¼ isopropanol) 54 2.16
13 Cetostearyl alcohol 53 2.12
14 Lanolin (¼wool fat) 49 1.96
15 Methylparaben (¼methyl parahydroxybenzoate) 47 1.88
16 Butylated hydroxytoluene (¼BHT) 42 1.68
17 Butylated hydroxyanisole (¼BHA) 41 1.64
18 Benzyl alcohol 36 1.44
19 Propylparaben (¼propyl parahydroxybenzoate) 35 1.40
20 Dimet(h)icone 34 1.36
21 Benzoic acid 29 1.16
22 Talc 21 0.84
23 Isopropyl miristate 20 0.80
24 Stearic acid 20 0.80
25 Hydroxypropylcellulose 19 0.76
26 Sodium laurylsulfate 19 0.76
27 Citric acid monohydrate 18 0.72
28 Poloxamer 18 0.72
29 Sorbitan 18 0.72
30 Sodium chloride 17 0.68
31 Sorbic acid (¼hexadienoic acid) 17 0.68
32 Hydroxyethylcellulose 16 0.64
33 Potassium sorbate 12 0.48
34 Povidone (¼polyvidone) 12 0.48
35 Phenylethyl alcohol (¼benzene ethanol) 11 0.44
36 Imidurea 10 0.40
37 Hydrochloric acid (¼chlorohydric acid) 10 0.40
38 Lactic acid (¼2-hydroxypropanoic acid) 10 0.40
39 Sorbitol 9 0.36
40 Diethanolamide 8 0.32
41 Castor oil 7 0.28
42 Phosphoric acid 7 0.28
43 Silicone 7 0.28
44 Sodium citrate 7 0.28
45 Titanium dioxide 7 0.28
46 Xanthan gum 7 0.28
47 Acetic acid (¼ethanoic acid) 6 0.24
48 Alpha tocopherol (¼vitamin E) 6 0.24
49 Diethanolamine (¼DEA) 6 0.24
50 Docusate sodium 6 0.24
51 Ethyl acetate 6 0.24
52 Medium-chain triglycerides 6 0.24
53 Phenoxyethanol 6 0.24
54 Chlorocresol 5 0.20
55 Peanut oil 5 0.20
56 Polyester 5 0.20
57 Sodium citrate anhydrous 5 0.20
58 Wax microcrystalline (¼petroleum wax) 5 0.20
59 Acetic acid, glacial 4 0.16
60 Almond oil 4 0.16
61 Cholesterol 4 0.16
62 Ethylene glycol palmitostearate 4 0.16
63 Ethylcellulose 4 0.16
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Table 1 (continued )
# Excipient NDD/excip Relative frequencyexcip (%)
64 Ethyl oleate 4 0.16
65 Kaolin 4 0.16
66 Menthol (¼hexahydrothymol) 4 0.16
67 Polyoxyethylen 4 0.16
68 Butylparaben (¼butyl parahydroxybenzoate) 3 0.12
69 Castor oil hydrogenated 3 0.12
70 Cyclomethicone (¼dimethylcyclopolysiloxane) 3 0.12
71 Gelatine 3 0.12
72 Oliv oil 3 0.12
73 Sodium phosphate, dibasic 3 0.12
74 Wax white 3 0.12
75 Ascorbic acid (¼vitamin C) 2 0.08
76 Benzyl benzoate 2 0.08
77 Cyclodextrin 2 0.08
78 Dimethyl 2 0.08
79 Edetic acid 2 0.08
80 Ethylparaben 2 0.08
81 Hypromellose 2 0.08
82 Isopropyl palmitate 2 0.08
83 Lactose 2 0.08
84 Magnesium silicate 2 0.08
85 Methylcellulose 2 0.08
86 Polyvinyl alcohol 2 0.08
87 Propyl gallate 2 0.08
88 Propylene carbonate (¼carbonic acid) 2 0.08
89 Sodium benzoate 2 0.08
90 Sodium bicarbonate 2 0.08
91 Starch maize 2 0.08
92 Wax emulsiﬁng non ionic (macrogol 800) 2 0.08
93 Ascorbyl palmitate (¼vitamin C palmitate) 1 0.04
94 Bentonite 1 0.04
95 Benzalkonium chloride 1 0.04
96 Bronopol 1 0.04
97 Cellulose acetate 1 0.04
98 Chlorhexidine 1 0.04
99 Crospovidone 1 0.04
100 Dextrin 1 0.04
101 Ethyl vanillin 1 0.04
102 Glucose, liquid 1 0.04
103 Glyceryl behenate 1 0.04
104 Lanolin alcohol (¼wool wax alcohol) 1 0.04
105 Lecithin 1 0.04
106 Lomexin 1 0.04
107 Oleic acid 1 0.04
108 Phenol (¼hydroxybenzene) 1 0.04
109 Phenylmercuric nitrate 1 0.04
110 Potassium chloride 1 0.04
111 Propylen glycol alginate 1 0.04
112 Simethicone 1 0.04
113 Sodium alginate 1 0.04
114 Starch 1 0.04
115 Triacetine (¼glycerol triacetate) 1 0.04
116 Triethyl citrate (¼citric acid) 1 0.04
117 Vanillin 1 0.04
SUM Nexcip,total¼2499 100.00
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The acetol content in FDC experiments was assayed using a high-
throughput GC-FID method. The GC apparatus consisted of a
separation module provided with a Flame Ionization Detector (FID)
controlled by TotalChrom (all Perkin Elmer, Massachusetts, USA).
GC separations were performed using an AT™–AQUAWAX(30 m 0.32 mm, 0.25 mm ﬁlm thickness) capillary column (Grace,
Berlin, Germany) maintained at 100 1C. Injector and detector
temperatures were both 250 1C. Nitrogen was used as a carrier
gas at a ﬂow rate of 0.5 mL/min. The injection volume was 1 μL
(split, 1:50). Total analysis time was 8 min. N-butanol was used as
internal standard.
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sample compounds (propylene glycol, and glycerol) was observed.
Linearity was assured in a working range of 14.53 mg/mL (LOQ)
up to 250 mg/mL. A recovery of 94.9274.30% (mean7RSD,
n¼3) was found. The LOD was determined to be 4.36 mg/mL.
Moreover, a precision of 1.8% (n¼9) at a concentration level of
100 mg/mL was observed.2.3.3. Franz diffusion cell experiments using human skin
Dermal absorption data of acetol in several dose formulations were
obtained using human split-thickness skin in a static FDC set-up
(Logan Instruments Corp., New Jersey, USA) with a receptor
compartment of 5 mL. All conditions were performed using a
randomized blocked design (n¼3–5). Excised human skin from
six female patients, who had undergone an abdominoplastic
procedure, was used (4975 years old, mean7SEM). Skin
preparation was made according to the internationally accepted
guidelines [6].
Immediately after the surgical removal, the skin was cleaned
with 0.01 M PBS (pH 7.4) and the subcutaneous fat was removed.
The skin samples were wrapped in aluminum foil and stored at
20 1C. Just before the experiments, the skin samples were
thawed and dermatomed to a pre-set thickness of 400 mm. The
experimentally obtained thickness of the skin, determined using a
micrometer (Mitutoyo, Tokyo, Japan), was 41677 mm (mean7
SEM, n¼66). Skin samples were sandwiched between the donor
and the receptor chambers of the diffusion cells (0.64 cm2
diffusion area) and held together with a clamp. The receptor
compartment was ﬁlled with receptor medium (i.e. 0.01 M PBS),
making sure all air under the skin was removed. The whole
assembly was ﬁxed on a magnetic stirrer and the solution in the
receptor compartment was continuously mixed using a Teﬂon
coated magnetic stirring bar (400 rpm). Before starting the skin
experiments, skin impedance was measured using an automatic
micro-processor controlled LCR Impedance Bridge (Tinsley,
Croydon, U.K.) in the R PAR 100 mode to ensure that there
was no skin damage (skin integrity test). Skin pieces with an
impedance value below 10 kΩ were discarded and replaced [7].
As no dermal exposure data are currently available for acetol, the
inﬁnite dose approach was preferred [8]. 500 mL of a 5% acetol
(m/V) solution in four different vehicles was brought on the skin:
propylene glycol/water (50/50, V/V), glycerol/water (50/50, V/V),
ethanol/water (50/50, V/V) and pure water. Concentrations in
these donor solutions were also experimentally determined by the
high-throughput GC-FID method and used in the calculations. The
donor compartment was then covered with Paraﬁlm (American
National Can™, Chicago, USA) and the temperature of the
receptor compartment was kept at 3271 1C by a water jacket.
FDC samples of the receptor ﬂuid (200 mL) were drawn at regular
time intervals from the sample port (1, 2, 4, 8, 12, 21 and 24 h)
and were immediately replaced by 200 mL fresh receptor ﬂuid
solution. The analytically determined acetol assay values in the
FDC samples were correspondingly corrected for the replenish-
ments. At the end of the experiment (i.e. after 24 h), the skin
surfaces were swabbed with cotton wool. The quantity of the
remained dose was determined by the GC-FID method. The
epidermis and dermis were separated with a tweezer and acetol
was extracted from both skin layers with ethanol to construct a
mass balance, with an overall recovered value of 116.0573.24%
(mean7SEM, n¼23).2.3.4. Kinetic analysis of Franz diffusion cell data
The skin permeation parameters were calculated from the linear portion
of the individual plots of the cumulative amount acetol permeated as a
function of time. After the equilibration phase, a linear relationship of
all individual curves (e.g. R2 not less than 0.869) was observed.
Moreover, steady-state and sink conditions were conﬁrmed: after 24 h,
only 1.3–10.0% of the dose applied was cumulatively found in the
receptor chamber. For ethanol as vehicle, the last time point was not
considered in further calculations. At this point, the cumulative curves
ﬂattened, indicating the loss of sink conditions.
The steady-state ﬂux (Jss) was obtained from the slope of the linear
part of the curve divided by 0.64 to correct for the exposed skin area.
The lag time (tlag) was estimated by extrapolating the linear portion of
the curve to the time-axis. The maximal absorption (Qmax,24 h),
expressed as percentage of the applied dose, was calculated as the
sum of the acetol quantity found in the receptor ﬂuid, epidermis and
dermis after 24 h. From these three experimentally secondary kinetic
parameters, the apparent primary transdermal parameters, i.e., the
permeability coefﬁcient Kp, the diffusion coefﬁcient Dm and skin/
dose-vehicle partitioning coefﬁcient Km, were calculated as follows [9]:
Kp ¼ Jss=Cv ð2Þ
where Cv is the experimentally determined concentration of acetol
in the dose formulation.
Dm ¼ d2=ð6tlagÞ ð3Þ
Km ¼ ðKpdÞ=Dm ð4Þ
where d is the measured tissue thickness.
To obtain the mean transdermal permeation parameters, the
individual values for each replication were averaged for the four
investigated conditions.3. Results
3.1. Impurities in topical excipients
A pharmaceutical excipient list was constructed (Table A.1) and
explored to obtain information about the absolute and relative
frequency of occurrence of these excipients in dermal drugs
(Table 1). From these data on, the cumulative frequency of dermal
excipients was calculated (Fig. 1). A large majority of dermal
drugs were composed of only a few different excipients. Indeed,
only 21 of the 117 excipients used in the dermal drugs (i.e. 18%)
represented 80% of the total use. Although water is the most
abundant excipient in dermal drugs, it will be excluded for further
investigation. For the remaining 20 most important excipients, all
impurities found in the pharmacopoeias, literature [10–29] and
from typical synthesis pathways are listed in Table 2.
Apart from the “generic” impurities like residual solvents, heavy
metals, pesticides, and mycotoxins [3,8], which were not the subject
of this investigation, the more structurally related impurities were
considered (n¼115, presented in italic in Table 2) and in-silico
evaluated on their intrinsic toxicity. It is interesting to note that the
different consulted pharmacopoeias sometimes indicate not only
different speciﬁcation limits for speciﬁed impurities, but even
different impurities. Moreover, the pharmacopoeias and literature
information also include impurity-classes, e.g. PAHs in parafﬁn,
petrolatum and pesticide residues in lanolin and organic
Fig. 1 Cumulative frequency (%) of excipients in topical drugs.
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unidentiﬁed impurities were searched in the literature: phenanthrene
was the only reported PAH impurity in petrolatum [20], while for
parafﬁn, phenanthrene [15], naphthalene [13], benzo[b]ﬂuor-
anthene and benzo[a]pyrene [14] have been speciﬁed. As parafﬁn
and petrolatum are both puriﬁed from crude oil, both excipients
are expected to contain the same PAH impurities. Therefore, all
these four PAHs will be included in the toxicity evaluation. On
the contrary, the exact structures of organic hydroperoxide
impurities were not further identiﬁed in the literature. Hence,
1-hydroperoxyethane-1,2-diol will be taken as the model com-
pound for the in-silico toxicity evaluation of this class of
impurities. Fig. 2 presents the in-silico (Derek Nexus) toxicity
information for all 115 impurities over the different toxicity
endpoints, subdivided in mammals or bacteria. Approximately
half (n¼23) of the 48 endpoints investigated by Derek Nexus
gave an alert for the topical excipient impurities. Possible alerts
for the endpoints are displayed with the level of likelihood, a
qualitative indication for the toxicity prediction of a chemical
(i.e. certain, probable, plausible, equivocal, doubted, improbable,
and impossible), which is determined by structure-activity
relationships ((Q)SARs) and other expert knowledge rules.
Empty cells in the matrix of Fig. 2 indicate that no structural
alerts were found in the compound for the corresponding end-
point (e.g. carcinogenicity in butan-1-ol). This implies that there
is no evidence of toxicity, nor evidence of non-toxicity.3.2. Toxicity priority list of the impurities found in topical
excipients and choice of acetol
A toxicity priority list (Table 3) of the investigated impurities was
derived from the in-silico toxicity outcome in Fig. 2.
Toxicity class “Zprobable” represents impurities having a level of
likelihood of “probable” for at least one endpoint, class “plausible”
encloses impurities having a level of likelihood of “plausible” for at
least one endpoint and class “requivocal” contains impurities with a
level of likelihood of “equivocal” or lower.
The toxicity class “Zprobable” encompasses impurities for
which the risk after dermal exposure has already been investi-
gated, i.e. PAHs [30], propylene oxide [31], acetaldehyde [32],
formaldehyde [33], benzene [34], furfural [35], methanol [36],
acrolein [37], dihydroxyacetone [38], phenol [39], hydroquinone
[40], p-methoxyphenol [41], p-cresol [42] and phthalic anhy-
dride [43]. Due to the chemical and physical instability of
allylchloride [44], and hazardous gasses like ethylene oxide and
benzoyl chloride, their presence in topical formulations contact-
ing the skin is highly questionable. Moreover, dermal assess-
ment data are available for ethylene oxide [45,46]. The second
class of impurities contains a variety of compounds with
“plausible” toxicity. Considering the relative frequency of
occurrence of excipients in the dermal drugs, acetol (1-hydro-
xypropan-2-one or 1-hydroxyacetone) was found to be the most
important impurity. This hydrophilic low mass molecule
(MW¼74 g/mol, log Pow¼0.78) has been reported in two
excipients i.e. propylene glycol and glycerol. After water,
propylene glycol is the most abundantly present topical exci-
pient and together with glycerol, they represent 11% of excipients
use in topical drugs. Exposure to other impurities from this second
Table 2 Impurities of the most common topical excipients
Excipient Ph. Eur. (limit) USP (limit) Ph. Int. (limit) Literature Other possible
impurities
Propylene
glycol
Heavy metals (5 mg/mL);
sulfated ash (0.01%)
Heavy metals (5 mg/mL); chloride
(0.007%); sulfate (0.006%)
Heavy metals (5 mg/mL); sulfated ash
(0.01%)
Acetol [10]; dipropylene glycol [11];
tripropylene glycol [11]; diethylene
glycol [12]
Alpha-phenylethanol,
propylene; oxide;
ethylbenzene; styrene;
ethylbenzene
hydroperoxide
Parafﬁn PAHs; sulfates (150 mg/mL);
sulfated ash (0.05%)
PAHs; sulfur compounds Sulfated ash (0.1%) Naphthalene [13];benzo[a]pyrene [14]; benzo
[b]ﬂuoranthene [14]; phenanthrene [15]
n/a
Polyethylene
glycol
Formaldehyde (30 mg/mL); ethylene glycol;
diethylene glycol; ethylene oxide (1 mg/mL);
1,4-dioxan (10 mg/mL); sulfated ash (0.20 %);
heavy metals (20 mg/mL)
Ethylene oxide (10 mg/mL); 1,4-
dioxan (10 mg/mL); ethylene
glycol; diethylene glycol
Diethylene glycol; heavy metals
(50 mg/mL); sulfated ash (1%)
Acetaldehyde [12]; formaldehyde; formic acid
[16]; organic hydroperoxide [17]; free
ethylene oxide; 1,4-dioxane; ethylene glycol;
diethylene glycol [18]
n/a
Ethanol Acetal; acetaldehyde; acetone; benzene (2 mg/
mL); cyclohexane; methanol (100
mg/mL); methyl ethyl ketone (butan-2-one);
methyl isobutyl ketone; propan-1-ol;
isopropanol (propan-2-ol); butan-1-ol; butan-
2-ol; 2-methylpropanol (isobutanol); furfural;
2-methylpropan-2-ol; 2-methylbutan-2-ol;
pentan-2-ol; pentan-1-ol; hexan-1-ol; heptan-
2-ol; hexan-2-ol; hexan-3-ol
Methanol (100 mg/mL); acetal;
acetaldehyde; benzene (2 mg/mL)
Aldehydes methanol benzene Acetaldehyde; isobutyl acetate; diethylacetal;
crotonaldehyde; 1,1-diethoxypentane [19]
n/a
Petrolatum PAH; sulfated ash (0.05%) n/a Sulfated ash (0.10%) Phenanthrene derivates [20] n/a
Carbomer Free acrylic acid (0.25%); benzene
(2 mg/mL); sulfated ash (4%); heavy metals
(20 mg/mL)
Acrylic acid (0.25%);
benzenea(2 mg/mL); heavy metals
(20 mg/mL); ethyl acetatec (0.5%);
cyclohexaneb (0.3%)
Sulfated ash (0.10%) Furfural [21] Acetaldehyde;
formaldehyde; acrolein;
methylfuran; furfural
Glycerol Diethylene glycol (0.05%); ethylene glycol;
propylene glycol; aldehydes (10 mg/mL);
esters; halogenated compounds (35 mg/mL);
sugars; chlorides (10 mg/mL); sulfated ash
(0.01%); heavy metals (5 mg/mL)
Chloride (0.001%); sulfate
(0.002%); heavy metals (5 mg/mL);
chlorinated compounds (0.003%);
fatty acids; esters; diethylene glycol
(0.025%); ethylene glycol (0.025%)
Heavy metals (5 mg/mL); chlorides
(10 mg/mL); sulfates (20 mg/mL);
sulfated ash (0.10%); water (2%);
chlorinated compounds; fatty acids and
esters; aldehydes and reducing
substances
Acetol [10]; glyceraldehyde [22];
dihydroxyacetone [22]; acrolein [23]
Dichlorohydrin;
epichlorohydrin;, 1,3-
propanediol; propylene
glycol; allylchloride; di-
and tripropylene glycol;
propene
Sodium
hydroxide
Carbonates (2%); chlorides (50 mg/mL);
sulfates (50 mg/mL); iron (10 mg/mL); heavy
metals (20 mg/mL)
Potassium; heavy metals (0.003%);
sodium carbonate (3%)
Heavy metals (10 mg/mL); arsenic
(4 mg/mL); aluminum, iron and
insoluble matter in HCl; potassium;
sulfates (1200 mg/mL); chlorides
(700 mg/mL)
n/a n/a
Trolamine Ethanolamine (0.10%); diethanolamine
(0.50%); N-nitrosodiethanolamine
(24 ng/mL); sulfated ash (0.10%);
heavy metals (10 mg/mL)
n/a n/a n/a n/a
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Table 2 (continued )
Excipient Ph. Eur. (limit) USP (limit) Ph. Int. (limit) Literature Other possible
impurities
Cetyl alcohol n/a n/a Sulfated ash (0.1%); parafﬁn Stearyl alcohol [24]; myristyl alcohol [24];
lauryl alcohol [24]
n/a
Isopropyl
alcohol
Acetone; benzene (1 mg/mL);
di-isopropyl ether; diethylether; methanol;
propan-1-ol
Diethylether; di-isopropylether;
acetone; butan-2-ol
Aldehydes and ketones n/a n/a
Cetostearyl
alcohol
n/a n/a Parafﬁn Octa-, nonadecane; eicosane, henicosane; 1-
do-,tri-, tetra-, penta-, hexa-; heptadecanol; 2-
tetra-, penta-, hexa-, hepta-, octa-,
nonadecanol; 3-tetra-, penta-, hexa-, hepta-,
octa-, nonadecanol; do-, tri-, tetra-, penta-,
hexa-, hepta-, octadecanal [25]
n/a
Lanolin BHT (200 mg/mL); parafﬁn (1%); pesticides
residues (1 mg/mL); chlorides (150 mg/mL);
sulfated ash (0.15%)
Chloride (0.035%); ammonia;
pesticide residues (40 mg/mL);
petrolatum
Parafﬁn; ammonia Chlorfenvinphos; cypermethrin;
diazinon [26]
n/a
Methyl
paraben
4-Hydroxybenzoic acid (0.50%);
ethylparaben; propylparaben; butylparaben;
sulfated ash (0.10%)
n/a Sulfated ash (0.10%) n/a Phenol
Benzyl
alcohol
Benzaldehyde (0.15%); cyclohexylmethanol
(0.10%)
Cyclohexylmethanol; benzaldehyde Chlorinated compounds; aldehydes;
sulfated ash (0.05%)
Benzaldehyde dibenzylacetal [27]; dibenzyl
ether [28]
Benzylchloride;
dibenzylether
BHA Hydroquinone (0.20%); heavy metals
(10 mg/mL)
Heavy metals (0.001%) Hydroquinone; sulfated ash (0.10%) n/a Paramethoxyphenol;
isobutene
BHT Sulfated ash (0.10%) Heavy metals (0.001%) Hydroquinone; sulfated ash (0.10%) n/a p-Cresol, isobutene
Propyl
paraben
4-Hydroxybenzoic acid (0.50%);
methylparaben (0.50%); ethylparaben
(0.50%); butylparaben (0.50%); sulfated ash
(0.10%)
n/a Sulfated ash (0.10%) n/a Phenol
Dimethicone Heavy metals (5 mg/mL) Heavy metals (5 mg/mL); bacterial
endotoxins (10 endotox u/mL)
n/a n/a Chlorotrimethylsilane;
dichlorodimethylsilane
Benzoic acid Sulfated ash (0.10%) Heavy metals (10 mg/mL) Heavy metals (20 mg/mL) Phthalic acid [29] Toluene;
benzoylchloride;
benzotrichloride;
phthalic anhydride
Ph. Eur.:European Pharmacopoeia, 7th ed. European Directorate for the Quality of Medicines and Healthcare. Strassbourg, France, 2010–2013.
USP: United States Pharmacopeia, USP 35/NF30. The United States Pharmacopeial Convention. Rockville, MD, USA, 2012.
Ph. Int.: International Pharmacopoeia. WHO. Genève, Switzerland, 2012.
n/a: not available.
Related impurities are presented in italic.
aResidual solvent class 1.
bResidual solvent class 2.
cResidual solvent class 3. n/a: not available.
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Fig. 2 Toxicity database of related impurities in topical excipients. Legend: ’ Probable; Plausible; Equivocal; Doubted;
improbable; Impossible. Species: Mammal (M); Bacteria (B). Control compounds are given in italic.
Risk evaluation of impurities in topical excipients 311toxicity class “plausible”, which are present in more than one
excipient (e.g. phenol), occurs at a much lower relative frequencyexcip
(approximately 5%). Moreover, dermal absorption data of acetol are
lacking, emphasizing the need to investigate acetol.
3.3. Dermal study using human skin
Quantitative transdermal parameters for acetol were obtained using
human skin (gold standard). Two examined vehicles, propylene glycol/
water (50/50, V/V) and glycerol/water (50/50, V/V), are representative
in-use conditions of dermal products. To implement the Kp sensitivity
towards the choice of the solvent, 5% acetol in water and in ethanol/
water (50/50, V/V) were also incorporated in the experimental design.
Fig. 3 shows typical plots of the cumulative amount penetrated through
the skin (mg) versus time (h) for each of the investigated formulations.
Their mean transdermal parameters are given in Table 4.
The steady-state apparent skin permeability of acetol in ethanol/
water (50/50, V/V) (Kp¼3.91 103 cm/h) was signiﬁcantly
higher than in the other vehicles. This is not unexpected as ethanol
is a well-known penetration enhancer, decreasing the barrier resistance
by i.a. dissolving SC lipids [47]. The permeability coefﬁcients of acetol
in the other dose vehicles, also reported to be penetration enhancers
[47–49], were more comparable (Kp,water and PG¼1.30 103 cm/h4
Kp,glycerol¼7.78 104 cm/h).4. Discussion
Dermal drug excipients are mostly used in much higher quantities
than APIs, contrasting other dosage forms like oral tablets.However, unlike APIs and packaging material, the formal regula-
tions on pharmaceutical excipients are rather limited. In recent
ICH Q8/Q9 and EC directive 2011/62/EU, excipients are men-
tioned rather vague, requiring the holders of the manufacturing
authorization to ensure the suitability of excipients in medicinal
products. Although European authorities recognize the need for
formal guidelines with draft proposals being issued, the addition of
more speciﬁc GMPs for some categories of excipients (among
them propylene glycol and glycerol) was drawn back. Never-
theless, some authorities are in the process of assuring the
excipient quality system in one or another way [50]. Lacking an
explicit formal excipient control, IPEC and partner organizations
like EFCG are developing their own voluntary GMP guidelines
[51]. Moreover, major pharmaceutical companies are aware of
quality issues related to the use of topical excipients, and are
currently tackling these [52].
Therefore, we ﬁrst established a list of all excipients used in
preparations for cutaneous applications, and focused on the 20
most important excipients. Next, we looked at all possible
(related) impurities of these 20 excipients, and evaluated their
toxicity by an in-silico approach. From the toxicity priority list,
the impurity with the highest toxicity concern for which no
dermal exposure data are available, i.e. acetol, was selected in
order to assess its risk when dermally applied in relevant dermal
drug excipients (i.e. propylene glycol and glycerol). Although
the in-vitro mutagenic properties of acetol were demonstrated
with positive Ames tests [53–56] and with in-silico Derek
Nexus evaluation, EFSA reported it is not likely for acetol to be
genotoxic in-vivo [57]. Acetol is thus classiﬁed as Cramer
structural class I [57,58], with a TTC of 1800 mg/(day∙person)
Table 3 In-silico toxicity impurity list of dermal excipients.
Class Impurities #
ZProbable Propylene oxide; benzo[a]pyrene; naphthalene; acetaldehyde; ethylene oxide; formaldehyde; benzene; furfural; methanol;
acrolein; allylchloride; dihydroxyacetone; phenol; hydroquinone; p-methoxyphenol; p-cresol; benzoylchloride; phthalic
anhydride
19
Plausible Acetol; ethylbenzene hydroperoxide; styrene; phenanthrene; formic acid; 1-hydroperoxyethane-1,2-diol; acetal;
2-methylbutan-2-ol; 2-methylpropan-1-ol (isobutanol); 2-methylpropan-2-ol; propan-1-ol; propan-2-ol (isopropyl alcohol);
butan-1-ol; butan-2-ol; crotonaldehyde; heptan-2-ol; hexan-1-ol; hexan-2-ol; hexan-3-ol; diethylacetal; 1,1-diethoxypentane;
pentan-1-ol; pentan-2-ol; benzo[b]ﬂuoranthene; glyceraldehyde; dichlorohydrin; epichlorohydrin; diethanolamine;
ethanolamine; N-nitrosodiethanolamine; laurylalcohol; myristylalcohol; stearylalcohol; 1-dodecanol; 1-tridecanol;
1-tetradecanol; 1-pentadecanol; 1-hexadecanol; 1-heptadecanol; 2-tetradecanol; 2-pentadecanol; 2-hexadecanol;
2-heptadecanol; 2-octadecanol; 2-nonadecanol; 3-tetradecanol; 3-pentadecanol; 3-hexadecanol; 3-heptadecanol;
3-octadecanol; 3-nonadecanol; dodecanal; tridecanal; tetradecanal; pentadecanal; hexadecanal; heptadecanal;
octadecanal; benzylchloride; cyclohexylmethanol; chlorotrimethylsilane; dichlorodimethylsilane; benzotrichloride
62
rEquivocal Alpha-phenylethanol; ethylbenzene; propylene glycol: dipropylene glycol; tripropylene glycol; 1,4-dioxan; diethylene
glycol; ethylene glycol; methyl isobutyl ketone; methyl ethyl ketone (butan-2-one); cyclohexane; isobutyle acetate; acetone;
acrylic acid; methylfuran; 1,3-propanediol; propene; diisopropylether; diethylether; octadecane; nonadecane; eicosane;
henicosane; 4-hydroxybenzoic acid; ethylparaben; propylparaben; methylparaben; butylparaben; benzaldehyde dibenzyl
acetal; benzaldehyde; dibenzylether; isobutene; toluene; phthalic acid
34
Fig. 3 Typical ﬂux curves of acetol in the investigated vehicles.
Legend: ( ) pure water, ( ) ethanol/water (50/50, V/V), ( )
propylene glycol/water (50/50, V/V), and ( ) glycerol/water
(50/50, V/V).
J. Boonen et al.312[59]. The estimated food exposure of acetol as food ﬂavoring
substance [FL-no 07.169], i.e. 0.22 mg/(day∙person), does not exceed
this class I threshold and hence the EFSA panel concluded that acetol
at its current use in food is safe.
Originally, the TTC approach was only used for the safety
assessment of ﬂavoring substances, but has recently been extended
towards the risk assessment of impurities in therapeutic drugs and
cosmetic ingredients [60]. It was concluded that the existing oral TTC
values can also be used for dermal exposure, provided that some route-
to-route extrapolations are considered, principally to cover the differ-
ence in bioavailability. In this study, the bioavailability after dermal
exposure to acetol was addressed by performing an ex-vivo in-vitro
transdermal experiment. Additionally, the bioavailability depends on
the metabolization in the skin. Acetol is metabolized to endogenous
compounds (methylglyoxal, pyruvate and glucose) in the methyl-
glyoxal pathway [57]. All involved enzymes (CYP2E1, glutathione-
S-transferase, alcohol dehydrogenase and aldehyde dehydrogenase) are
also present in the skin, but their activities are lower than in other
tissues [61,62]. Moreover, these enzymes are largely inactivated in
once-frozen excised skin [6,63]. A slight overestimation ofunmetabolized acetol reaching the systemic circulation after dermal
exposure can thus be expected in our experiments.
As acetol is an impurity in the frequently used topical excipients
propylene glycol and glycerol, limit speciﬁcations in these excipients
were set by comparing the TTC of 1800 mg/(day∙person) with the
systemic exposure as deﬁned by the Ofﬁce of Solid Waste and
Emergency Response (OSWER) equation [64]:
DDE¼ ð½acetolKpSA ED EF EV teventÞ=ðBW ATÞ ð5Þ
DDE is the systemic exposure to acetol after dermal drug
application under pre-deﬁned circumstances. To minimize the
risk of acetol, this value may thus not exceed the TTC-value of
1800 mg/(day∙person). The acetol exposure concentration in a
dermally applied drug, [acetol], can be split up in the concentration
of acetol in the excipient (i.e. speciﬁcation limit) and the concentra-
tion of this excipient (propylene glycol or glycerol) in the dermal
formulation. For information towards the latter, the THERIAQUEs
database was consulted. The concentration (%, m/m) of excipient in
the dermal drug formulation covering 65% of the total population
was considered as an appropriate estimate in our limit speciﬁcation
calculations. Concentrations of propylene glycol and glycerol in
dermal formulations were in this way estimated to be 10% (m/m)
and 5% (m/m), respectively (Fig. 4).
The apparent permeability coefﬁcient Kp for acetol was ob-
tained from the in-vitro transdermal FDC experiment. The overall
Kp (meanþ1SD) of the different formulations, i.e. acetol in water,
in 50% EtOH, in 50% PG and 50% glycerol, was calculated to be
2.5 103 cm/h. This value is intended to be an averaged
estimate. The head, arms and hands were considered as the treated
skin area (SA), which corresponds to 0.4991 m2 (meanþ1SD) for
an adult man [65]. The exposure duration (years) (ED) for non-
carcinogenic chemical exposure is equivalent to the averaging time
(days) (AT) i.e. 25 years (9125 days). For a (worst case) chronic
treatment, applied once a day (event frequency (EV)¼1 event/
day), the exposure frequency (EF) was supposed to be 365 days/
year. The event duration (tevent) was estimated to be 16 h/event, as
a person is assumed to apply the formulation in the morning and
will rinse it off before sleeping. Hence, using the DDE formula
Table 4 Transdermal parameters for acetol in the different vehicles (mean7RSD (%)).
Condition Observed secondary parameters Apparent primary parameters
Jss (mg/cm
2/h) Qmax,24 h Lag time (h) Kp (10
3 cm/h) Dm (10
4 cm2/h) Km
H2O 68.3721.2 3.37711.7 2.95771.0 1.30721.2 1.28749.6 0.55777.2
50% EtOH 170.0745.1 7.28729.0 2.14751.8 3.91745.1 1.49741.8 1.19748.0
50% PG 84.6779.0 2.94776.0 5.65770.9 1.30779.0 1.077103.0 1.24791.5
50% Glycerol 58.3739.9 1.75739.0 4.39728.7 0.78740.3 0.73722.4 0.50761.4
Fig. 4 Cumulative frequency (%) of (A) propylene glycol and (B) glycerol in dermal drugs.
Risk evaluation of impurities in topical excipients 313and setting DDE¼1800 mg/(day person), the speciﬁcation limits
for acetol in propylene glycol and glycerol were calculated to be
90 mg/mL (parts per million) and 180 mg/mL, respectively.
HPLC–UV analysis of acetol in propylene glycol and glycerol
market samples gave values ranging between 3 and 80 mg/mL [10],
indicating compliance with the proposed dermal speciﬁcation limits.
Of course, the calculated speciﬁcation limits are only applicable for
dermal exposure to acetol. Assuming a bioavailability of 100% after
oral intake, more strict limits are expected to be set. Although most
quality regulatory guidelines still do not make a distinction between
the applied routes of administration, it is justiﬁed to apply other
speciﬁcation limits depending on the intended administration route.
Moreover, in a QbD approach, a ﬁxed limit can be avoided by
consulting a suitable design space (e.g. concentration of acetol in
excipient concentration of excipient in the formulation). In our
approach, we assumed that only one of both excipients (propylene
glycol or glycerol) is present in the dermal drug formulation. If both
excipients are present in the formulation, the overall dermal
speciﬁcation limit (in propylene glycol plus glycerol) obviously
needs to be lowered. Moreover, the dermal formulation in which
the impurity occurs inﬂuences the Kp and hence the systemic
exposure. For each exposure condition to a speciﬁc dermal formula-
tion e.g. in the case when other components might be designed to
improve drug absorption, deviating speciﬁcation limits can be
expected. As mentioned before, propylene glycol and glycerol are
penetration enhancers themselves, but very often other penetration
enhancing excipients, like ethanol, or penetration enhancing bioactive
compounds, like spilanthol [66,67], are present in the topical drug
formulation. Different models and literature describe the skin
permeation inﬂuence of accompanying compounds [68–70], but
further elaboration of their impacts is beyond the scope of this work.
Summarized, in this study, a risk priority list of related
impurities in excipients for topical use was made. This central
tool can be applied to judge the safety of pharmaceuticalexcipients. Moreover, it emphasizes that a more strict regulatory
quality control for excipients is justiﬁed and that a case-by-case
evaluation is required. In a study with acetol as important impurity
in propylene glycol and glycerol, we introduce a general approach
that can serve as risk assessment GMP guideline for hazardous
impurities in dermally used excipients. It allows to set quantitative
speciﬁcation limits, which can be used in a ﬁrst step to manage the
possible risk of uncontrolled pharmaceutical excipients.
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